PCSK9 and familial hyperaldosteronism: Considering that the intestine influences the overall lipid levels via lipid absorption and that the direct effects of PCSK9 inhibition are centered on hepatic pathways (as hepatic PCSK9 plays the major role in cholesterol regulation), targeting PCSK with novel medication, including evolocumab, alirocumab, and inclisiran, is a promising option for non-responders to 1st and 2nd line FH treatment [116].